• ARCA EGFP mRNA for LNP Transfection Workflows

  2026-08-23

  ARCA EGFP mRNA provides a fast, direct fluorescence readout for optimizing mammalian-cell transfection and benchmarking lipid nanoparticle delivery. Its ARCA cap and approximately 100-nucleotide poly(A) tail make it especially useful when researchers need to distinguish delivery failure from weak translation or unstable RNA.

• Oseltamivir acid: Influenza Neuraminidase Inhibitor

  2026-08-22

  Oseltamivir acid is an influenza neuraminidase inhibitor and the active metabolite of oseltamivir phosphate. Its defined solubility, antiviral mechanism, resistance relevance, and preclinical breast cancer findings make it a useful compound for influenza antiviral research and translational assay development.

• CTP Solution: From Nucleotide Stock to mRNA Assay

  2026-08-21

  CTP Solution is more than an IVT ingredient: its purity, pH, concentration, and handling characteristics can influence RNA workflow control. This article connects Cytidine-5'-triphosphate quality decisions with the localized p21 mRNA-LNP bladder cancer study and practical assay design.

• Forsythoside E: PKM2 Inhibitor Workflow

  2026-08-20

  Build a mechanism-led macrophage workflow around Forsythoside E, linking PKM2 tetramerization, glycolytic restraint, STAT3 phosphorylation suppression, and M2 polarization. The guide separates validated product parameters from practical assay recommendations for cell studies and sepsis-induced liver injury research.

• Dinaciclib in Cell Cycle and Boundary Research

  2026-08-20

  Dinaciclib (SCH727965) combines high-potency inhibition of CDK1, CDK2, CDK5, and CDK9 with practical readouts for cell-cycle and apoptosis studies. This workflow connects cancer-cell assays with boundary-aware imaging inspired by new Drosophila morphogenesis research, while clearly separating validated applications from exploratory extensions.

• Astrocytic GAT-3 in Dentate Gyrus Synaptic Control

  2026-08-19

  The reference study identifies astrocytic GAT-3 as an active regulator of dentate gyrus synaptic transmission rather than merely a GABA clearance system. Its experiments connect GAT-3-dependent astrocytic Ca2+ signaling to presynaptic GluN2B-containing NMDA receptors and contextual fear memory, providing a mechanistic framework for glia-focused synaptic transmission research.

• Salvianolic Acid B Targets LH2 in Pulmonary Fibrosis

  2026-08-19

  The reference study identifies Salvianolic acid B as a natural product that suppresses lysyl hydroxylase 2 expression, limits collagen cross-linking, and reduces fibrotic remodeling in cellular and pulmonary fibrosis models. Its findings support LH2-associated extracellular matrix remodeling as a mechanistic research target while leaving questions about direct enzyme inhibition, pharmacokinetics, and clinical translation.

• Cannabidiol, Orofacial Pain, and Affective Recovery

  2026-08-18

  A 2026 Brain Research Bulletin study shows that cannabidiol reduces inflammatory pain while also improving anxiety-like, depression-like, and cognitive abnormalities in mice. Its major contribution is a multi-level mechanism linking peripheral inflammation, trigeminal and pain-control circuits, endocannabinoid signaling, and central amygdala serotonin dynamics.

• Eltanexor (KPT-8602) Research Workflows

  2026-08-18

  Eltanexor (KPT-8602) enables mechanism-led studies of XPO1 inhibition across leukemia, lymphoma, colorectal cancer, and organoid models. Its strongest use-case differentiation is the ability to connect nuclear protein retention with apoptosis, Wnt/β-catenin modulation, and practical biomarker development.

• Salvianolic Acid B, LH2, and Pulmonary Fibrosis

  2026-08-17

  The reference study identifies Salvianolic acid B (Dan Shen Suan B) as an inhibitor of LH2-associated collagen cross-linking in pulmonary fibrosis models. By combining molecular, cellular, and tissue-level analyses, the authors link LH2 suppression with reduced collagen deposition, epithelial–mesenchymal transition, fibroblast activation, and Wnt/β-catenin signaling.

• p38α MAPK Dephosphorylation: A Dual-Action Strategy

  2026-08-17

  The reference study shows that kinase inhibitors can do more than block catalysis: selected compounds also expose the p38α MAPK activation-loop phosphosite to WIP1, accelerating dephosphorylation. This structure-guided mechanism provides a framework for designing inhibitors that combine direct kinase suppression with enhanced pathway shutdown, while also clarifying the limits of translating the finding into disease models.

• Corynoline Drives Osteosarcoma Apoptosis via Src/JNK

  2026-08-16

  The reference study identifies Corynoline as a growth-suppressive alkaloid in osteosarcoma and links its activity to Src/JNK signaling, G2/M arrest, and mitochondrial apoptosis. Its integrated computational, cellular, and xenograft design provides a useful framework for connecting pathway perturbation with cell death analysis while highlighting the limits of pharmacologic pathway validation.

• NSC-23766: Rac GTPase Inhibitor Guide

  2026-08-15

  NSC-23766 is a Rac GTPase inhibitor that blocks Rac1 activation by interfering with Trio and Tiam1 guanine nucleotide exchange factor interactions. It is a research tool for Rac1 signaling pathway studies, endothelial-barrier assays, apoptosis induction in breast cancer cells, and hematopoietic stem/progenitor-cell mobilization.

• EdU Imaging Kits (Cy5): Practical Workflow

  2026-08-15

  EdU Imaging Kits (Cy5), SKU K1076, provide a click-chemistry workflow for detecting DNA synthesis during S phase by fluorescence microscopy or flow cytometry. They are appropriate for fixed-cell proliferation and genotoxicity assessment workflows, but EdU incorporation alone should not be interpreted as proof of completed cell division, viability, or a specific DNA-damage mechanism.

• Epigenetic Immune Signatures in Melanoma

  2026-08-14

  Anichini et al. systematically compared immune-related transcriptional responses elicited by five epigenetic drug strategies in melanoma and identified guadecitabine as the strongest inducer of innate immune programs. The study connects tumor-cell profiling with patient biopsies and survival datasets, offering a framework for selecting epigenetic agents for combination immunotherapy while clarifying the limits of cross-model interpretation.

451 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page